Tolerability profile of cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis: factors contributing to treatment completion overall and in patients with high disease activity in the 96-week CLARITY study

被引：0
|
作者：
Vermersch, P.
Comi, G.
Cook, S.
Giovannoni, G.
Rammohan, K.
Rieckmann, P.
Sorensen, P. Soelberg
Kurukulasuriya, N.
Viglietta, V.
Chang, P.
Papasouliotis, O.
Greenberg, S.
机构：
[1] Univ Lille Nord de France, Lille, France
[2] Univ Vita Salute San Raffaele, Milan, Italy
[3] Univ Med & Dent, Newark, NJ USA
[4] Barts & London Queen Marys Sch Med & Dent, London, England
[5] Univ Miami, Miami, FL USA
[6] Univ Erlangen Nurnberg, Bamberg, Germany
[7] Copenhagen Univ Hosp, Copenhagen, Denmark
[8] Merck Serono SA, Geneva, Switzerland
来源：
JOURNAL OF NEUROLOGY | 2011年 / 258卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：259 / 259
页数：1
相关论文
共 50 条
  • [41] Cladribine tablets in high disease activity (HDA) subgroups from the CLARITY study of patients with relapsing multiple sclerosis (RMS)
    Giovannoni, G.
    Rammohan, K.
    Cook, S.
    Comi, G.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Dangond, F.
    Hicking, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 203 - 204
  • [42] COST-EFFECTIVENESS ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Dineva, T.
    Panayotov, P.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S206 - S206
  • [43] Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis
    Giovannoni, Gavin
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Hamlett, Anthony
    Viglietta, Vissia
    Greenberg, Steven
    LANCET NEUROLOGY, 2011, 10 (04): : 329 - 337
  • [44] Cladribine tablets in patients who had failed prior treatment with injectable disease-modifying drugs for relapsing-remitting multiple sclerosis: evaluation of treatment effect in the CLARITY study
    Cook, S.
    Comi, G.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    Scarramozza, M.
    Chang, P.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2011, 258 : 260 - 260
  • [45] Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England
    Hettle, Robert
    Harty, Gerard
    Wong, Schiffon L.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (07) : 676 - 686
  • [46] Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
    Giovannoni, Gavin
    Sorensen, Per Soelberg
    Cook, Stuart
    Rammohan, Kottil W.
    Rieckmann, Peter
    Comi, Giancarlo
    Dangond, Fernando
    Hicking, Christine
    Vermersch, Patrick
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (06) : 819 - 827
  • [47] Magnetic resonance imaging (MRI) outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets: results from the CLARITY study, a 96-week, phase III, double-blind, placebo-controlled trial
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Fevr, T.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2009, 256 : S49 - S50
  • [48] CLARITY extension: sustained efficacy in relapsing remitting multiple sclerosis following switch from cladribine tablets to placebo in patients with high disease activity at baseline
    Vermersch, P.
    Giovannoni, G.
    Soelberg-Sorensen, P.
    Keller, B.
    Jack, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 867 - 867
  • [49] Evaluation of the Treatment Effect of Cladribine Tablets in the Cohort of Patients Who Had Failed Prior Treatment with Injectable Disease-Modifying Drugs: The CLARITY Relapsing-Remitting Multiple Sclerosis Study
    Cook, Stuart
    Comi, Giancarlo
    Giovannoni, Gavin
    Rammohan, Kottil
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Scaramozza, Matthew
    Chang, Peter
    Greenberg, Steven J.
    NEUROLOGY, 2011, 76 (09) : A322 - A323
  • [50] Positive impact of cladribine tablets on reducing brain atrophy in patients with relapsing-remitting multiple sclerosis: A longitudinal study
    Achiron, Anat
    Warszawer, Yehuda
    Nissan, Yael
    Kerpel, Ariel
    Hoffmann, Chen
    Harari, Gil
    Magalashvili, David
    Tal, Sigal
    MULTIPLE SCLEROSIS JOURNAL, 2025,
12345